Answers are grounded in this paper and cite their sources.
virus PCR. Th e culture grew Pseudomonas stutzeri . AZA was held and the patient was treated with cefepime for 2 weeks. Th e patient recovered from the meningitis but continued to have diarrhea with moderate-to-severe endoscopic disease activity. Given the severity of her disease, primary non-response to certolizumab and the fact that her infection was adequately controlled with antibiotics, Vedolizumab treatment was eventually resumed along with a tapering course of prednisone. Th e patient, however, ultimately required fecal diversion for persistent disease activity. Patients with CD are at an increased risk for serious infections, due to both diseaserelated infections and immunosuppressive therapies ( 2 ). By selectively inhibiting α 4β 7 integrin interaction with mucosal addressin cell-adhesion molecule (MAdCAM1), vedolizumab blocks T-lymphocyte traffi cking to the gut and nasopharynx where MAdCAM1 is expressed on the vascular endothelium. Th e phase 3 randomized controlled trial for CD revealed a slightly higher numeric but not statistically signifi cant risk for serious infections with VDZ as compared with placebo (relative risk 1.48, 95% confi dence interval: 0.67, 3.24) ( 1 ). During the phase 3 trials for ulcerative colitis and CD, 2 cases of viral meningitis and 1 case of Listeria meningitis were reported in vedolizumab-treated patients ( 3 ). Th e case of Listeria meningitis occurred in the setting of concomitant AZA therapy and systemic steroids. Although an estimated 10% of the population is colonized with Listeria monocytogenes , listeriosis is typically only seen in immunosuppressed individuals ( 4 ). Th e occurrence of Listeria meningitis may potentially have been secondary to gut translocation in an immunosuppressed individual. Pseudomonas stutzeri , an aerobic Gramnegative bacillus, is typically an asymptomatic colonizer of the respiratory tract and rarely pathogenic. Although bacteremia and pneumonia have been reported, meningitis is extremely rare with <5 cases reported to date, all in the setting of systemic immune suppression ( 5–8 ). Our patient was receiving AZA and budesonide and had only recently discontinued certolizumab. Th e timing of infection with initiation of vedolizumab, however, raises the possibility of a Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease
No takes yet. Share an insight, caveat, or question.
Boland et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: